161 related articles for article (PubMed ID: 37283962)
1. Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial.
Mo ZJ; Huang SJ; Qiu LX; Li CG; Yu XJ; Li MQ; Chen Z; Zhong GH; Pan DQ; Huang LR; Lv BJ; Cui XL; Song QQ; Jia JZ; Han JL; Wang W; Zhu H; Cheng T; Su YY; Li YM; Ye XZ; Wu T; Zhang J; Xia NS
Lancet Reg Health West Pac; 2023 May; 34():100707. PubMed ID: 37283962
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
Pan HX; Qiu LX; Liang Q; Chen Z; Zhang ML; Liu S; Zhong GH; Zhu KX; Liao MJ; Hu JL; Li JX; Xu JB; Fan Y; Huang Y; Su YY; Huang SJ; Wang W; Han JL; Jia JZ; Zhu H; Cheng T; Ye XZ; Li CG; Wu T; Zhu FC; Zhang J; Xia NS
Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38614117
[TBL] [Abstract][Full Text] [Related]
3. Development of a skin- and neuro-attenuated live vaccine for varicella.
Wang W; Pan D; Fu W; Ye X; Han J; Yang L; Jia J; Liu J; Zhu R; Zhang Y; Liu C; Ye J; Selariu A; Que Y; Zhao Q; Wu T; Li Y; Zhang J; Cheng T; Zhu H; Xia N
Nat Commun; 2022 Feb; 13(1):824. PubMed ID: 35149692
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children.
Namazova-Baranova L; Habib MA; Povey M; Efendieva K; Fedorova O; Fedoseenko M; Ivleva T; Kovshirina Y; Levina J; Lyamin A; Ogorodova L; Reshetko O; Romanenko V; Ryzhenkova I; Sidorenko I; Yakovlev Y; Zhestkov A; Tatochenko V; Scherbakov M; Shpeer EL; Casabona G;
Hum Vaccin Immunother; 2022 Jan; 18(1):1959148. PubMed ID: 34435933
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
8. Rational Design of a Skin- and Neuro-Attenuated Live Varicella Vaccine: A Review and Future Perspectives.
Wang W; Pan D; Cheng T; Zhu H
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632591
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
12. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study.
Huang L; Chen Z; Song Y; Tan J; Jia N; You W; Yuan H; Feng G; Li C; Luan C; Quan Y; Wang Y
Vaccine; 2024 Jan; 42(2):396-401. PubMed ID: 38057208
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.
Mitra M; Faridi M; Ghosh A; Shah N; Shah R; Chaterjee S; Narang M; Bhattacharya N; Bhat G; Choudhury H; Kadhe G; Mane A; Roy S
Hum Vaccin Immunother; 2015; 11(2):443-9. PubMed ID: 25692656
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months.
Ramkissoon A; Coovadia HM; Jugnundan P; Haffejee IE; Meurice F; Vandevoorde D
S Afr Med J; 1995 Dec; 85(12):1295-8. PubMed ID: 8600589
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
